

# HEMATOLOGY AND ONCOLOGY FOR USMLE

## Myelodysplastic Syndromes (MDS) & Myeloproliferative Neoplasms (MPNs)

These are clonal hematopoietic stem cell disorders, but they differ fundamentally:

- MDS → ineffective production (cytopenias)
- MPNs → excessive production (cytoses)

Think of them as opposite ends of the myeloid spectrum



## MYELODYSPLASTIC SYNDROMES (MDS)



### Definition

Clonal stem cell disorders characterized by:

- Ineffective hematopoiesis
- Dysplastic maturation of non-lymphoid cells

- Bone marrow blasts < 20%
- Risk of transformation to AML

More common in older adults 🧓

---

## Etiology

De novo mutations (most common)

OR

Environmental exposure:

- Radiation 🚫
- Benzene 🧪
- Chemotherapy

These cause genomic instability in hematopoietic stem cells.

---

## Pathophysiology

Stem cell mutation → Abnormal myeloid maturation →  
Ineffective hematopoiesis → Increased apoptosis in  
marrow → Cytopenias (anemia, neutropenia,  
thrombocytopenia)

If mutation burden increases → Blasts rise →  $\geq 20\%$   
blasts → Transformation to AML 🔥

---



## Pseudo-Pelger-Huët Anomaly

Neutrophils with:

- Bilobed nuclei ("duet" nuclei) 🎵
- Hyposegmented appearance

Seen in:

- MDS
- Certain drugs (immunosuppressants)

📌 High-yield morphology clue.

---



## MDS vs AML

Feature	MDS	AML
Blasts	< 20%	≥ 20%
Onset	Gradual	Acute
Marrow	Dysplastic	Packed with blasts
Risk	May progress	Already malignant



## MYELOPROLIFERATIVE NEOPLASMS (MPNs)

These are malignant clonal disorders with increased production of mature myeloid cells.

Unlike MDS, these have overproduction rather than failure.

# Polycythemia Vera (PV)

## Genetics

Acquired JAK2 mutation (very high yield)

JAK2 mutation → Constitutive tyrosine kinase activation  
→ Cytokine-independent erythropoiesis → Increased RBC production

---

## Mechanism Flowchart

JAK2 mutation → Constant activation of JAK-STAT pathway → Increased RBC production → Hyperviscosity → Thrombosis risk

---

## Clinical Features

- Aquagenic pruritus (itching after hot shower) 
- Erythromelalgia (burning red-blue extremities) 
- Thrombosis (DVT, PE, Budd-Chiari)

- Hyperviscosity symptoms

 EPO levels ↓ (distinguishes from secondary polycythemia)

---

## Treatment

- Phlebotomy
  - Hydroxyurea
  - Ruxolitinib (JAK1/2 inhibitor)
- 

## 2 Essential Thrombocythemia (ET)

### Genetics

- Often JAK2 mutation (30–50%)
- 

### Pathophysiology

Megakaryocyte proliferation → Massive platelet production → Thrombosis + bleeding

Why bleeding?

Platelets may be dysfunctional.

---

### Features

- Very high platelet count
  - Large, abnormal platelets on smear
  - Erythromelalgia may occur
- 

## ③ Primary Myelofibrosis

### Pathophysiology

Atypical megakaryocyte hyperplasia → Increased TGF- $\beta$  secretion → Fibroblast activation → Bone marrow fibrosis → Marrow failure

---

## Splenomegaly

Megakaryocyte proliferation → TGF- $\beta$  release →  
Fibroblast activation → Bone marrow fibrosis →  
Extramedullary hematopoiesis → Massive splenomegaly

---

## Classic Findings

- "Teardrop" RBCs 
- Dry tap on bone marrow aspiration
- Massive splenomegaly

 "Bone marrow cries because it's fibrosed."

---



## MPN Comparison Table

Disease	RBCs	WBCs	Platelets	Philadelphia Chromosome	JAK2
Polycythemia vera	↑	↑	↑	-	+
Essential thrombocythemia	-	-	↑	-	+(30-50%)
Myelofibrosis	↓	Variable	Variable	-	+(30-50%)
CML	↓	↑	↑	-	+

## 4 Chronic Myelogenous Leukemia (CML)



### Genetics

- Philadelphia chromosome
  - t(4;22)
  - BCR-ABL fusion protein
  - Constitutive tyrosine kinase activation
- 

 Mechanism

BCR-ABL → Constant proliferative signaling → Excess myeloid cells → Marked leukocytosis

---

 Leukemoid Reaction vs CML

Feature	Leukemoid Reaction	CML
Definition	Reactive neutrophilia (>50,000)	Myeloproliferative neoplasm
BCR-ABL	-	+

Neutrophils	Toxic granulation, Döhle bodies	Pseudo-Pelger-Huët
LAP score	↑	↓
Eosinophils/ Basophils	Normal	Increased

 Exam Trick:

Low LAP score = CML

High LAP score = Leukemoid reaction

---

 Exam Points

- Aquagenic pruritus = Polycythemia vera
- EPO ↓ = PV (primary cause)
- Teardrop RBCs + massive spleen = Myelofibrosis
- BCR-ABL = CML
- LAP low = CML

- Bilobed neutrophils = MDS
  - Blasts  $\geq 20\%$  = AML
- 

## Big Picture Comparison

MDS  $\rightarrow$  defective maturation  $\rightarrow$  cytopenias

MPN  $\rightarrow$  excessive proliferation  $\rightarrow$  cytos

If the exam shows:

Elderly + cytopenias + dysplastic cells  $\rightarrow$  MDS

If the exam shows:

Elevated counts + JAK2 or BCR-ABL mutation  $\rightarrow$  MPN

---

## POLYCYTHEMIA

Polycythemia = increased hemoglobin/hematocrit.

But the mechanism differs

---

## Classification Table

Type	Plasma Volume	RBC Mass	O <sub>2</sub> Sat.	EPO Level	Associations
Relative	↓	-	-	-	Dehydration, burns
Appropriate Absolute	-	↑	↓	↑	Lung disease, congenital heart disease, high altitude, OSA
Inappropriate Absolute	-	↑	-	↑	Exogenous EPO, androgen use, RCC, HCC
Polycythemia Vera (PV)	-	↑ ↑	-	↓	JAK2 mutation

 Key idea:

Absolute polycythemia = ↑ RBC mass

Relative polycythemia = ↓ plasma volume

## Mechanism Flowcharts

### Relative Polycythemia

Fluid loss  $\rightarrow$   $\downarrow$  Plasma volume  $\rightarrow$  Hemoconcentration  $\rightarrow$   
 $\uparrow$  Hematocrit (false increase)

---

### Appropriate Absolute Polycythemia

Hypoxia (lung disease, high altitude)  $\rightarrow$  Kidney senses  $\downarrow$   
 $O_2$   $\rightarrow$   $\uparrow$  EPO production  $\rightarrow$   $\uparrow$  RBC mass

  $O_2$  saturation  $\downarrow$

 EPO  $\uparrow$

---

### Inappropriate Absolute Polycythemia

Normal oxygen levels  $\rightarrow$  Tumor or drug secretes EPO  $\rightarrow$   
 $\uparrow$  RBC mass

Common causes:

- Renal cell carcinoma (RCC)
- Hepatocellular carcinoma (HCC)
- Exogenous EPO (athletes "blood doping" 🏃)

📌 O<sub>2</sub> normal

📌 EPO elevated

---

## ● Polycythemia Vera (Primary)

JAK2 mutation → Constitutive JAK-STAT activation →  
Erythropoiesis independent of EPO → ↑ ↑ RBC mass

Negative feedback → Suppressed renal EPO production →  
↓ EPO levels

📌 High-yield distinction:

PV = RBC ↑ + EPO ↓

---

## 🧬 Chromosomal Translocations

---



## Translocation Summary Table

Translocation	Disorder	Key Gene Effect
t(8;14)	Burkitt lymphoma	c-MYC activation
t(11;14)	Mantle cell lymphoma	Cyclin D1 activation
t(11;18)	Marginal zone lymphoma	MALT pathway
t(14;18)	Follicular lymphoma	BCL-2 activation
t(15;17)	Acute promyelocytic leukemia (APL)	PML-RARA fusion
t(9;22)	CML ( $\pm$ ALL)	BCR-ABL



### Why Ig Heavy Chain Is Important

Chromosome 14 contains Ig heavy chain genes, which are constantly active in B cells.

If oncogenes (c-MYC, BCL-2, Cyclin D1) get translocated next to chromosome 14:

Ig heavy chain promoter → Continuous gene expression  
→ Oncogene overexpression → Malignant proliferation



---

## Langerhans Cell Histiocytosis (LCH)

### Definition

A proliferative disorder of Langerhans cells (antigen-presenting dendritic cells normally in skin).

---

### Classic Presentation

Child with:

- Lytic bone lesions
- Skin rash
- Recurrent otitis media

- Mastoid bone mass
- 

## Pathophysiology

Abnormal Langerhans cell proliferation → Functionally immature cells → Poor T-cell stimulation → Tissue infiltration

---

## Key Markers

- S-100 positive
- CD1a positive
- Birbeck granules on EM

Birbeck granules:

- Rod-shaped
  - "Tennis racket" appearance 
  - Very classic exam clue.
-

## 💥 Tumor Lysis Syndrome (TLS)

An oncologic emergency ⚠️

Occurs after rapid tumor cell destruction (often lymphomas/leukemias).

Can happen:

- After chemotherapy
  - Spontaneously in fast-growing cancers
- 

### 🔄 Pathophysiology Flowchart

Massive tumor cell lysis → Release of intracellular contents

→ ↑ Potassium

→ ↑ Phosphate

→ ↑ Nucleic acids

Nucleic acids → Broken down into uric acid →  
Hyperuricemia

Phosphate binds calcium  $\rightarrow$   $\downarrow$  Calcium (hypocalcemia)

Resulting in:

- Arrhythmias ⚡
- Seizures
- Tetany
- Acute kidney injury

---

 Laboratory Pattern

Electrolyte	Change
$K^+$	$\uparrow$
$PO_4^{3-}$	$\uparrow$
Uric acid	$\uparrow$
$Ca^{2+}$	$\downarrow$

---

## Complications

- ECG changes
- Muscle weakness
- Calcium phosphate crystals in kidney
- Uric acid crystals
- Acute renal failure

---

## Prevention & Treatment

High-risk patient → Aggressive IV hydration

Prevention:

- Allopurinol (inhibits xanthine oxidase)
- Rasburicase (breaks down uric acid)

 Rasburicase works faster → used in high-risk patients.

## Exam Points

- RBC ↑ + EPO ↓ = Polycythemia vera
  - RBC ↑ + EPO ↑ + hypoxia = Appropriate secondary polycythemia
  - t(15;17) = APL → treat with ATRA
  - Birbeck granules = Langerhans cell histiocytosis
  - Hyperkalemia + hyperphosphatemia + hypocalcemia after chemo = Tumor lysis syndrome
- 

-> The End <-